The status of allopurinol in the management of tumor lysis syndrome: a clinical review.
Hagemeister
Fredrick
F
Department of Lymphoma, MD Anderson Cancer Center, Houston, Texas, USA. fhagemei@mdanderson.org
Huen
Auris
A
D000493:Allopurinol / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D000963:Antimetabolites / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D006947:Hyperkalemia / Q000209:etiology / Q000378:metabolism; D033461:Hyperuricemia / Q000209:etiology; D007262:Infusions, Intravenous; D010710:Phosphates / Q000378:metabolism; D012307:Risk Factors; D015275:Tumor Lysis Syndrome / Q000188:drug therapy*; D014503:Urate Oxidase / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use
D000963:Antimetabolites; D010710:Phosphates; C469709:rasburicase; D000493:Allopurinol; D014503:Urate Oxidase